Request Trial
15 May 2013Americas

IP key to US biosimilars success – report

Strong IP knowledge is one of four key factors to succeeding in the burgeoning US biosimilars market, according to an industry report.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
ITC to probe Oura Ring after Samsung retaliates, seeking import ban
15 January 2026   The wearable tech fight continues as Samsung seeks to block US sales of the Finnish brand's product after being sued over its Galaxy Ring.
Americas
Speciality pharma firm stumbles on bid to enforce Belbuca ruling
15 January 2026   A court has blocked the patent owner's latest attempt to stop a generic rival as it weighs the right way to challenge a new product.
Americas
Why the US is poised for a patent litigation surge in 2026
12 January 2026   After “seismic” changes imposed by the USPTO last year, litigating patents will become significantly more difficult and costly to defend, and both plaintiffs and defendants must urgently retool their strategies, advise lawyers from BCLP.


Editor's picks

Final call: Who are the world’s best in-house counsel?
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

Editor's picks

Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025

More features

Senior four-partner team leaves A&O Shearman
Final call: Who are the world’s best in-house counsel?
ITC to probe Oura Ring after Samsung retaliates, seeking import ban
Speciality pharma firm stumbles on bid to enforce Belbuca ruling
Italian medtech startup beats larger US rival in UPC dispute
Senior USPTO solicitor steps into private practice
Goodwin targets transatlantic patent work with London hire
Bayer secures key Denmark ruling as Xarelto faces expiry pressure